Inovio Pharmaceuticals, Inc. (BMV:INO)

Market Cap	1.95B +36.2%
Revenue (ttm)	1.18M -70.0%
Net Income	-1.53B
EPS	-32.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Average Volume	296
Open	29.80
Previous Close	29.00
Day's Range	29.80 - 29.80
52-Week Range	25.00 - 57.00
Beta	n/a
RSI	44.18
Earnings Date	Feb 27, 2026

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 134
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: INO

Financial Performance

In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.

Financial numbers in USD